Latest Serotonin-norepinephrine reuptake inhibitor Stories
MONTCLAIR, N.J., Sept. 22 /PRNewswire/ -- The American Society of Pain Educators (ASPE) recently launched, the second of a three-part Webcast series: Is Your Persistent Chronic Pain Weighing You Down? at http://www.painawareness.org/.
To: MEDICAL EDITORS Contact: Charles McAtee, Eli Lilly and Company, +1-317-277-1566; or Eva Freitag, Boehringer Ingelheim, + 49 (6132) 77-2964 INDIANAPOLIS, Aug.
The American Society of Pain Educators (ASPE) announces the launch of an educational Webcast series on chronic pain with leading health specialists and Olympic Games gold medalist and chronic pain sufferer, Nikki Stone.
CHARLOTTE, N.C., July 23, 2008 (PRIME NEWSWIRE) -- Chelsea Therapeutics International, Ltd.
INDIANAPOLIS, June 27 /PRNewswire-FirstCall/ -- Eli Lilly and Co and Boehringer Ingelheim today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has issued a positive opinion supporting the approval of Cymbalta(R) (duloxetine hydrochloride) for the treatment of Generalised Anxiety Disorder (GAD).
WALTHAM, Mass., June 18 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that Lexapro is the leading single agent used in anxiety therapy with 11.7 percent and 14.9 percent of first- and second-line patient share, respectively.
Eli Lilly and Co. said the U.S. Food and Drug Administration has approved duloxetine HCl, marketed under the name Cymbalta, for fibromyalgia. The Indianapolis drug maker said Cymbalta is the first serotonin-norepinephrine reuptake inhibitor proven to give relief to patients with the pain disorder.
Eli Lilly and Company has announced that the FDA has approved Cymbalta for the management of fibromyalgia, a chronic widespread pain disorder.
The U.S. Food and Drug Administration (FDA) has approved Cymbalta(R) (duloxetine HCl) for the management of fibromyalgia, a chronic widespread pain disorder, Eli Lilly and Company (NYSE: LLY) announced today.
WALTHAM, Mass., June 3 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that, despite physicians' desire to prescribe more serotonin/norepinephrine reuptake inhibitors (SNRIs), Forest Laboratories' Lexapro retains leadership among first-line therapies in the treatment of major depression.